{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:17:45Z","timestamp":1790723865279,"version":"4.1.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,6,12]],"date-time":"2013-06-12T00:00:00Z","timestamp":1370995200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s40272-013-0032-6","type":"journal-article","created":{"date-parts":[[2013,6,11]],"date-time":"2013-06-11T11:15:28Z","timestamp":1370949328000},"page":"377-391","source":"Crossref","is-referenced-by-count":34,"title":["Combination Pharmacotherapy for Psychiatric Disorders in Children and Adolescents: Prevalence, Efficacy, Risks and Research Needs"],"prefix":"10.1007","volume":"15","author":[{"given":"Jon","family":"Jureidini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Tonkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Jureidini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,6,12]]},"reference":[{"issue":"6","key":"32_CR1","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1517\/14740338.6.6.695","volume":"6","author":"JA Salazar","year":"2007","unstructured":"Salazar JA, Poon I, Nair M. Clinical consequences of polypharmacy in elderly: expect the unexpected, think the unthinkable. Expert Opin Drug Saf. 2007;6(6):695\u2013704.","journal-title":"Expert Opin Drug Saf"},{"key":"32_CR2","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jaac.2010.07.007","volume":"49","author":"JS Comer","year":"2010","unstructured":"Comer JS, Olfson M, Mojtabai R. National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996\u20132007. J Am Acad Child Adolesc Psychiatry. 2010;49:1001\u201310.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"7","key":"32_CR3","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.euroneuro.2009.04.003","volume":"19","author":"G Goodwin","year":"2009","unstructured":"Goodwin G, Fleischhacker W, Arango C, et al. Advantages and disadvantages of combination treatment with antipsychotics. Eur Neuropsychopharmacol. 2009;19(7):520\u201332.","journal-title":"Eur Neuropsychopharmacol"},{"key":"32_CR4","doi-asserted-by":"crossref","unstructured":"Joshi G, Gerogiopoulos AM. Combination pharmacotherapy for psychiatric disorders in children and adolescents. Rosenberg DR, Gershon S (eds) Pharmacotherapy of child and adolescent psychiatric disorders, chap. 17. 3rd ed. New York: Wiley; 2012.","DOI":"10.1002\/9781119958338.ch17"},{"issue":"1","key":"32_CR5","first-page":"18","volume":"3","author":"HA Pincus","year":"2004","unstructured":"Pincus HA, Tew JD, First MB. Psychiatric comorbidity: is more less? World Psychiatry. 2004;3(1):18\u201323.","journal-title":"World Psychiatry"},{"key":"32_CR6","unstructured":"Beddoe R. Dying for a cure. New York: Random House; 2007."},{"key":"32_CR7","doi-asserted-by":"crossref","unstructured":"Rashed AN, Wong ICK, Cranswick N, et al. Risk factors associated with adverse drug reactions in hospitalised children: international multicentre study. Eur J Clin Pharmacol. 2011. doi: 10.1007\/s00228-011-1183-4 .","DOI":"10.1007\/s00228-011-1183-4"},{"key":"32_CR8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/08897070903442665","volume":"31","author":"Y Kaminer","year":"2010","unstructured":"Kaminer Y, Goldberg P, Connor DF. Psychotropic medications and substances of abuse interactions in youth. Subst Abuse. 2010;31:53\u20137.","journal-title":"Subst Abuse"},{"key":"32_CR9","doi-asserted-by":"crossref","unstructured":"Muscatello MR, Spina E, Bandelow B, Baldwin DS. Clinical relevant drug interactions in anxiety disorders. Human Psychopharmacol Clin Exp. 2012. doi: 10.1002\/hup.2217 . Accessed 29 Mar 2012.","DOI":"10.1002\/hup.2217"},{"key":"32_CR10","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1159\/000319744","volume":"86","author":"R Schellander","year":"2010","unstructured":"Schellander R, Donnerer J. Antidepressants: clinically relevant drug interactions to be considered. Pharmacology. 2010;86:203\u201315.","journal-title":"Pharmacology"},{"issue":"7","key":"32_CR11","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0149-2918(08)80047-1","volume":"30","author":"E Spina","year":"2008","unstructured":"Spina E, Santoro V, D\u2019Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Therap. 2008;30(7):1206\u201327.","journal-title":"Clin Therap"},{"key":"32_CR12","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1517\/14740338.7.5.587","volume":"7","author":"C Sun-Edelstein","year":"2008","unstructured":"Sun-Edelstein C, Tepper SJ, Shapiro RE. Drug-induced serotonin syndrome: a review. Expert Opin Drug Safety. 2008;7:587\u201396.","journal-title":"Expert Opin Drug Safety"},{"key":"32_CR13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2165\/00002018-200225020-00004","volume":"25","author":"F Pisani","year":"2002","unstructured":"Pisani F, Oteri G, Costa C, et al. Effects of psychotropic drugs on seizure threshold. Drug Safety. 2002;25:91\u2013110.","journal-title":"Drug Safety"},{"key":"32_CR14","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1176\/appi.ps.000642011","volume":"62","author":"H Chen","year":"2011","unstructured":"Chen H, Patel A, Sherer J, et al. The definition and prevalence of pediatric psychotropic polypharmacy. Pyschiatric Serv. 2011;62:1450\u20135.","journal-title":"Pyschiatric Serv"},{"key":"32_CR15","doi-asserted-by":"crossref","first-page":"240","DOI":"10.4088\/JCP.08m04212","volume":"70","author":"RS McIntyre","year":"2009","unstructured":"McIntyre RS, Jerrell JM. Polypharmacy in children and adolescents treated for major depressive disorder: a claims database study. J Clin Psychiatry. 2009;70:240\u20136.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"32_CR16","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.clinthera.2010.04.021","volume":"32","author":"RJ Constantine","year":"2010","unstructured":"Constantine RJ, Boaz T, Tandon R. Antipsychotic polypharmacy in the treatment of children and adolescents in the fee-for-service component of a large state medicaid program. Clin Therap. 2010;32(5):949\u201359.","journal-title":"Clin Therap"},{"issue":"3","key":"32_CR17","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1089\/cap.2006.16.273","volume":"16","author":"AJ Dean","year":"2006","unstructured":"Dean AJ, McDermott BM, Marshall RT. Psychotropic medication utilization in a child and adolescent mental health service. J Child Adolescent Psychopharmacol. 2006;16(3):273\u201385.","journal-title":"J Child Adolescent Psychopharmacol"},{"key":"32_CR18","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s10826-010-9372-9","volume":"19","author":"AK Griffith","year":"2010","unstructured":"Griffith AK, Huscroft-D\u2019Angelo J, Epstein MH, et al. Psychotropic medication use for youth in residential treatment: a comparison between youth with monopharmacy versus polypharmacy. J Child Fam Stud. 2010;19:795\u2013802.","journal-title":"J Child Fam Stud"},{"key":"32_CR19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1745-0179-2-25","volume":"2","author":"PSS Russell","year":"2006","unstructured":"Russell PSS, George C, Mammen P. Predictive factors for polypharmacy among child and adolescent psychiatry inpatients. Clin Pract Epidemiol Mental Health. 2006;2:25.","journal-title":"Clin Pract Epidemiol Mental Health"},{"key":"32_CR20","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00023210-200620080-00002","volume":"20","author":"J Jureidini","year":"2006","unstructured":"Jureidini J, Tonkin A. Overuse of antidepressant drugs for the treatment of depression. CNS Drugs. 2006;20:623\u201332.","journal-title":"CNS Drugs"},{"key":"32_CR21","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1345\/aph.1M326","volume":"43","author":"CA Fontanella","year":"2009","unstructured":"Fontanella CA, Bridge JA, Campo JV. Psychotropic medication changes, polypharmacy and the risk of early readmission in suicidal adolescent inpatients. Ann Pharmacother. 2009;43:1939\u201347.","journal-title":"Ann Pharmacother"},{"key":"32_CR22","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1089\/cap.2009.0003","volume":"19","author":"H Zoega","year":"2009","unstructured":"Zoega H, Baldursson G, Hrafnkelsson B, et al. Psychotropic drug use among Icelandic children: a nationwide population-based study. J Child Adolesc Psychopharmacol. 2009;19:757\u201364.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"32_CR23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1753-2000-2-26","volume":"2","author":"JM Zito","year":"2008","unstructured":"Zito JM, Safer DJ, Jon-van den Berg LTW, et al. A three-country comparison of psychotropic medication prevalence in youth. Child Adolesc Psychiatry Mental Health. 2008;2:26.","journal-title":"Child Adolesc Psychiatry Mental Health"},{"key":"32_CR24","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/JCP.0b013e3181a20c8a","volume":"29","author":"T Gerhard","year":"2009","unstructured":"Gerhard T, Chavez B, Olfson M, et al. National patterns of the outpatient pharmacological management of children and adolescents with autism spectrum disorder. J Clin Psychopharmacol. 2009;29:307\u201310.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"32_CR25","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1542\/peds.2007-0212","volume":"121","author":"JM Zito","year":"2008","unstructured":"Zito JM, Safer DJ, Sai D, et al. Psychotropic medication patterns among youth in foster care. Pediatrics. 2008;121(1):e157\u201363.","journal-title":"Pediatrics"},{"key":"32_CR26","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1089\/cap.2005.15.12","volume":"15","author":"FF Duffy","year":"2005","unstructured":"Duffy FF, Narrow WE, Rae DS, et al. Concomitant pharmacotherapy among youths treated in routine psychiatric practice. J Child Adolesc Psychopharmacol. 2005;15:12\u201325.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"32_CR27","unstructured":"National Collaborating Centre for Mental Health. CG72 Attention deficit hyperactivity disorder (ADHD): full guideline. UK: The British Psychological Society and The Royal College of Psychiatrists; 2009. http:\/\/www.nice.org.uk\/nicemedia\/live\/12061\/42060\/42060.pdf ."},{"key":"32_CR28","unstructured":"National Collaborating Centre for Mental Health. CG28 Depression in Children and Young People. Identification and management in primary, community and secondary care. UK: The British Psychological Society and The Royal College of Psychiatrists; 2005."},{"key":"32_CR29","doi-asserted-by":"crossref","unstructured":"Martin A, Scahill L, Kratochvil C. Pediatric psychopharmacology principles and practice. 2nd ed. Oxford: Oxford University of Press; 2011.","DOI":"10.1093\/med\/9780195398212.001.0001"},{"key":"32_CR30","doi-asserted-by":"crossref","unstructured":"Kutcher S, Chehil S. Physical treatments, Rutter\u2019s child and adolescent psychiatry. 5th ed. New York: Blackwell Publishing Limited; 2008.","DOI":"10.1002\/9781444300895.ch67"},{"key":"32_CR31","doi-asserted-by":"crossref","unstructured":"Rosenberg D, Gershon S (eds) Pharmacotherapy of child and adolescent psychiatric disorders. 3rd ed. Chichester: John Wiley & Sons; 2012.","DOI":"10.1002\/9781119958338"},{"key":"32_CR32","first-page":"1","volume":"20","author":"JN George","year":"2013","unstructured":"George JN, Vesely SK, Woolf SH. Conflicts of interest and clinical recommendations: comparison of two concurrent clinical practice guidelines for primary immune thrombocytopenia developed by different methods. Am J Med Qual. 2013;20:1\u20138.","journal-title":"Am J Med Qual"},{"key":"32_CR33","first-page":"9","volume":"48","author":"AACAP","year":"2009","unstructured":"AACAP. Practice parameter on the use of psychotropic medication in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2009;48:9.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"8","key":"32_CR34","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1097\/01.CHI.0000046893.27264.53","volume":"42","author":"RL Findling","year":"2003","unstructured":"Findling RL, McNamara NK, Gracious BL, et al. Combination lithium and divalproex sodium in pediatric bipolarity. J Am Acad Child Adolesc Psychiatry. 2003;42(8):895\u2013901.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"32_CR35","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1542\/peds.2011-2654","volume":"128","author":"Steering committee on quality improvement and subcommittee on attention-deficit\/hyperactivity disorder","year":"2011","unstructured":"Steering committee on quality improvement and subcommittee on attention-deficit\/hyperactivity disorder. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit\/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128:1007\u201322.","journal-title":"Pediatrics"},{"key":"32_CR36","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1176\/appi.ajp.160.3.438","volume":"160","author":"DJ Safer","year":"2003","unstructured":"Safer DJ, Zito JM, dosReis S. Concomitant psychotropic medication for youths. Am J Psychiatry. 2003;160:438\u201349.","journal-title":"Am J Psychiatry"},{"key":"32_CR37","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/archpsyc.1976.01770100079008","volume":"33","author":"R Gittelman-Klein","year":"1976","unstructured":"Gittelman-Klein R, Klein DF, Katz S, Saraf K, et al. Comparative effects of methylphenidate and thioridazine in hyperkinetic children, I: clinical results. Arch Gen Psychiatry. 1976;33:1217\u201331.","journal-title":"Arch Gen Psychiatry"},{"key":"32_CR38","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/000992280003900102","volume":"39","author":"DF Connor","year":"2000","unstructured":"Connor DF, Barkley RA, Davis HT. A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clin Pediatr. 2000;39:15\u201325.","journal-title":"Clin Pediatr"},{"key":"32_CR39","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1089\/cap.1995.5.191","volume":"5","author":"GA Carlson","year":"1995","unstructured":"Carlson GA, Rapport MD, Kelly KL, et al. Methylphenidate and desipramine in hospitalized children with comorbid behavior and mood disorders: separate and combined effects on behavior and mood. J Child Adolesc Psychopharmacol. 1995;5:191\u2013204.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"32_CR40","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2010.03.004","volume":"63","author":"D Moher","year":"2010","unstructured":"Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 Explanation and elaboration: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol. 2010;63:e1\u201337.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"32_CR41","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/chi.0b013e31815d9af7","volume":"47","author":"DR Palumbo","year":"2008","unstructured":"Palumbo DR, Sallee FR, Pelham WE, et al. Clonidine for attention-deficit\/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry. 2008;47(2):180\u20138.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"32_CR42","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1212\/WNL.58.4.527","volume":"58","author":"R Kurlan","year":"2002","unstructured":"Kurlan R, Tourette\u2019s Syndrome Study Group. Treatment of ADHD in children with tics. Neurology. 2002;58:527\u201336.","journal-title":"Neurology"},{"issue":"1","key":"32_CR43","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jaac.2011.10.012","volume":"51","author":"TE Wilens","year":"2012","unstructured":"Wilens TE, Bukstein O, Brams M, et al. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit\/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2012;51(1):74\u201385.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"32_CR44","doi-asserted-by":"crossref","first-page":"e1406","DOI":"10.1542\/peds.2010-1260","volume":"127","author":"SH Kollins","year":"2011","unstructured":"Kollins SH, Jain R, Brams M, et al. Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. Pediatrics. 2011;127(6):e1406\u201313.","journal-title":"Pediatrics"},{"issue":"9","key":"32_CR45","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/01.chi.0000169012.81536.38","volume":"44","author":"CJ Kratochvil","year":"2005","unstructured":"Kratochvil CJ, Newcorn JH, Arnold LE, et al. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry. 2005;44(9):915\u201324.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"32_CR46","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/01.chi.0000155320.52322.37","volume":"44","author":"H Abikoff","year":"2005","unstructured":"Abikoff H, McGough J, Vitiello B, et al. Sequential pharmacotherapy for children with comorbid attention-deficit\/hyperactivity and anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2005;44:5.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"32_CR47","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/YCO.0b013e328353d467","volume":"25","author":"P Hazell","year":"2012","unstructured":"Hazell P, Jairam R. Acute treatment of mania in children and adolescents. Curr Opin Psychiatry. 2012;25:264\u201370.","journal-title":"Curr Opin Psychiatry"},{"key":"32_CR48","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1089\/cap.2009.0008","volume":"19","author":"M Cannon","year":"2009","unstructured":"Cannon M, Pelham WH, Sallee R, CAT Study Team, et al. Effects of clonidine and methylphenidate on family quality of life in attention-deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19:511\u20137.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"8","key":"32_CR49","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/01.CHI.0000046908.27264.00","volume":"42","author":"PL Hazell","year":"2003","unstructured":"Hazell PL, Stuart JE. A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child Adolesc Psychiatry. 2003;42(8):886\u201394.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"32_CR50","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1177\/0883073811435243","volume":"27","author":"H Perera","year":"2012","unstructured":"Perera H, Jeewandara KC, Seneviratne S, et al. ADHD refractory to methylphenidate treatment: a double-blind, placebo-controlled study combined \u03a93 and \u03a96 supplementation in children with attention-deficit hyperactivity disorder. J Child Neurol. 2012;27:747.","journal-title":"J Child Neurol"},{"issue":"3","key":"32_CR51","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10578-011-0220-y","volume":"42","author":"SH Abbasi","year":"2011","unstructured":"Abbasi SH, Heidari S, Mohammadi MR, Tabrizi M, et al. Acetyl-l-carnitine as an adjunctive therapy in the treatment of attention-deficit\/hyperactivity disorder in children and adolescents: a placebo-controlled trial. Child Psychiatry Hum Dev. 2011;42(3):367\u201375.","journal-title":"Child Psychiatry Hum Dev"},{"issue":"12","key":"32_CR52","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1176\/appi.ajp.2009.09020233","volume":"166","author":"JC Blader","year":"2009","unstructured":"Blader JC, Schooler NR, Jensen PS, et al. Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy. Am J Psychiatry. 2009;166(12):1392\u2013401.","journal-title":"Am J Psychiatry"},{"issue":"5","key":"32_CR53","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/chi.0b013e3180323354","volume":"46","author":"JL Armenteros","year":"2007","unstructured":"Armenteros JL, Lewis JE, Davalos M. Risperidone augmentation for treatment-resistant aggression in attention-deficit\/hyperactivity disorder: a placebo-controlled pilot study. J Am Acad Child Adolesc Psychiatry. 2007;46(5):558\u201365.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"32_CR54","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1089\/cap.2009.0037","volume":"19","author":"CP Zeni","year":"2009","unstructured":"Zeni CP, Tramontina S, Ketzer CR, et al. Methylphenidate combined with aripiprazole in children and adolescents with bipolar disorder and attention-deficit\/hyperactivity disorder: a randomized crossover trial. J Child Adolesc Psychopharmacol. 2009;19(5):553\u201361.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"32_CR55","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1176\/appi.ajp.162.1.58","volume":"162","author":"RE Scheffer","year":"2005","unstructured":"Scheffer RE, Kowatch RA, Carmody TC, et al. Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilisation with divalproex sodium. Am J Psychiatry. 2005;162:58\u201364.","journal-title":"Am J Psychiatry"},{"key":"32_CR56","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-244X-4-9","volume":"4","author":"S Akhondzadeh","year":"2004","unstructured":"Akhondzadeh S, Mohammadi MR, Khademi M. Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial. BMC Psychiatry. 2004;4:9.","journal-title":"BMC Psychiatry"},{"issue":"1","key":"32_CR57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/cap.2010.0073","volume":"21","author":"LE Arnold","year":"2011","unstructured":"Arnold LE, Disilvestro RA, Bozzolo D, et al. Zinc for attention-deficit\/hyperactivity disorder: placebo-controlled double-blind pilot trial alone and combined with amphetamine. J Child Adolesc Psychopharmacol. 2011;21(1):1\u201319.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"32_CR58","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1753-2000-5-36","volume":"5","author":"CA Farmer","year":"2011","unstructured":"Farmer CA, Arnold LE, Bukstein OG, Findling RL, et al. The treatment of severe child aggression (TOSCA) study: design challenges. Child Adolesc Psychiatry Ment Health. 2011;5(1):36.","journal-title":"Child Adolesc Psychiatry Ment Health"},{"issue":"10","key":"32_CR59","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1097\/00004583-200210000-00011","volume":"41","author":"MP DelBello","year":"2002","unstructured":"DelBello MP, Schwiers ML, Rosenberg HL, et al. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry. 2002;41(10):1216\u201323.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"32_CR60","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.pnpbp.2009.09.012","volume":"34","author":"S Akhondzadeh","year":"2010","unstructured":"Akhondzadeh S, Fallah J, Mohammadi MR, et al. Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(1):32\u20136.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"7","key":"32_CR61","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.pnpbp.2010.07.005","volume":"34","author":"V Rezaei","year":"2010","unstructured":"Rezaei V, Mohammadi MR, Ghanizadeh A, Sahraian A, et al. Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(7):1269\u201372.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"5","key":"32_CR62","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/DBP.0b013e3181e121ed","volume":"31","author":"AD Sandler","year":"2010","unstructured":"Sandler AD, Glesne CE, Bodfish JW. Conditioned placebo dose reduction: a new treatment in attention-deficit hyperactivity disorder? J Dev Behav Pediatr. 2010;31(5):369\u201375.","journal-title":"J Dev Behav Pediatr"},{"issue":"5","key":"32_CR63","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1089\/cap.2008.0152","volume":"19","author":"TJ Spencer","year":"2009","unstructured":"Spencer TJ, Greenbaum M, Ginsberg LD, Murphy WR. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit\/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19(5):501\u201310.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"32_CR64","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1089\/cap.2008.0080","volume":"19","author":"FR Sallee","year":"2009","unstructured":"Sallee FR, Lyne A, Wigal T, McGough JJ. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit\/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19(3):215\u201326.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"32_CR65","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1089\/cap.2008.0125","volume":"19","author":"TE Wilens","year":"2009","unstructured":"Wilens TE, Hammerness P, Utziner L, et al. An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness. J Child Adolesc Psychopharmacol. 2009;19(5):485\u201392.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"32_CR66","doi-asserted-by":"crossref","unstructured":"Snyder R, Turgay A, Aman M, Risperidone Conduct Study Group, et al. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatr. 2002;41(9):1026\u201336.","DOI":"10.1097\/00004583-200209000-00002"},{"key":"32_CR67","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1176\/appi.ajp.159.8.1337","volume":"159","author":"MG Aman","year":"2002","unstructured":"Aman MG, DeSmedt G, Derivan A, The Risperidone Disruptive Behavior Study Group, et al. Risperidone treatment of children with disruptive behavior disorders and subaverage IQ: a double-blind, placebo-controlled study. Am J Psychiatry. 2002;159:1337\u201346.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"32_CR68","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1089\/1044546041649020","volume":"14","author":"MG Aman","year":"2004","unstructured":"Aman MG, Binder C, Turgay A. Risperidone effects in the presence\/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. J Child Adolesc Psychopharmacol. 2004;14(2):243\u201354.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"32_CR69","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1089\/cap.2006.0012","volume":"17","author":"WG Kronenberger","year":"2007","unstructured":"Kronenberger WG, Giauque AL, Lafata DE, et al. Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid ADHD, conduct\/oppositional-defiant disorder, and aggression: a prospective, open-label study. J Child Adolesc Psychopharmacol. 2007;17(3):334\u201347.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"32_CR70","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1089\/cap.2009.0030","volume":"19","author":"K Chang","year":"2009","unstructured":"Chang K, Nayar D, Howe M, et al. Atomoxetine as an adjunct therapy in the treatment of co-morbid attention-deficit\/hyperactivity disorder in children and adolescents with bipolar I or II disorder. J Child Adolesc Psychopharmacol. 2009;19(5):547\u201351.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"32_CR71","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/01.chi.0000189135.05060.8a","volume":"45","author":"RL Findling","year":"2006","unstructured":"Findling RL, McNamara NK, Stansbrey R, et al. Combination lithium and divalproex sodium in pediatric bipolar symptom restabilisation. J Am Acad Child Adolesc Psychiatry. 2006;45(2):142\u20138.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"12","key":"32_CR72","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1097\/00004583-200112000-00016","volume":"40","author":"V Kafantaris","year":"2001","unstructured":"Kafantaris V, Coletti DJ, Dicker R, et al. Adjunctive antipsychotic treatment of adolescents with bipolar psychosis. J Am Acad Child Adolesc Psychiatryr. 2001;40(12):1448\u201356.","journal-title":"J Am Acad Child Adolesc Psychiatryr"},{"issue":"4","key":"32_CR73","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1089\/104454601317261582","volume":"11","author":"V Kafantaris","year":"2001","unstructured":"Kafantaris V, Dicker R, Coletti DJ, et al. Adjunctive antipsychotic treatment is necessary for adolescents with psychotic mania. J Child Adolesc Psychopharmacol. 2001;11(4):409\u201313.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"11","key":"32_CR74","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S0006-3223(03)00067-2","volume":"53","author":"RA Kowatch","year":"2003","unstructured":"Kowatch RA, Sethuraman G, Hume JH, Kromelis M, et al. Combination pharmacotherapy in children and adolescents with bipolar disorder. Biol Psychiatry. 2003;53(11):978\u201384.","journal-title":"Biol Psychiatry"},{"issue":"Suppl 1","key":"32_CR75","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1016\/j.jad.2004.05.017","volume":"82","author":"MN Pavuluri","year":"2004","unstructured":"Pavuluri MN, Henry DB, Carbray JA, et al. Open-label prospective trial of risperidone in combination with lithium or divalproex sodium in pediatric mania. J Affect Disord. 2004;82(Suppl 1):S103\u201311.","journal-title":"J Affect Disord"},{"issue":"3","key":"32_CR76","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/01.chi.0000194566.86160.a3","volume":"45","author":"K Chang","year":"2006","unstructured":"Chang K, Saxena K, Howe M. An open-label study of lamotrigine adjunct or monotherapy for the treatment of adolescents with bipolar depression. J Am Acad Child Adolesc Psychiatry. 2006;45(3):298\u2013304.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"32_CR77","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1177\/0883073807302611","volume":"22","author":"MG Chez","year":"2007","unstructured":"Chez MG, Burton Q, Dowling T, et al. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. J Child Neurol. 2007;22(5):574\u20139.","journal-title":"J Child Neurol"},{"issue":"1","key":"32_CR78","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1089\/cap.2011.0027","volume":"22","author":"W Shamseddeen","year":"2012","unstructured":"Shamseddeen W, Clarke G, Keller MB, et al. Adjunctive sleep medications and depression outcome in the treatment of serotonin-selective reuptake inhibitor resistant depression in adolescents study. J Child Adolesc Psychopharmacol. 2012;22(1):29\u201336.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1\u20133","key":"32_CR79","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jad.2011.07.010","volume":"135","author":"DG Kondo","year":"2011","unstructured":"Kondo DG, Sung YH, Hellem TL, et al. Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study. J Affect Disord. 2011;135(1\u20133):354\u201361.","journal-title":"J Affect Disord"},{"issue":"5","key":"32_CR80","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1089\/cap.2009.0042","volume":"19","author":"J Wozniak","year":"2009","unstructured":"Wozniak J, Mick E, Waxmonsky J, et al. Comparison of open-label, 8-week trials of olanzapine monotherapy and topiramate augmentation of olanzapine for the treatment of pediatric bipolar disorder. J Child Adolesc Psychopharmacol. 2009;19(5):539\u201345.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"32_CR81","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1089\/cap.2008.0126","volume":"19","author":"P Hammerness","year":"2009","unstructured":"Hammerness P, Georgiopoulos A, Doyle R, et al. An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics. J Child Adolesc Psychopharmacol. 2009;19(5):493\u20139.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"32_CR82","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1089\/cap.2008.007","volume":"19","author":"CA Calarge","year":"2009","unstructured":"Calarge CA, Acion L, Kuperman S, et al. Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. J Child Adolesc Psychopharmacol. 2009;19(2):101\u20139.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"32_CR83","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.pnpbp.2004.10.013","volume":"29","author":"WM Bahk","year":"2005","unstructured":"Bahk WM, Shin YC, Woo JM, et al. Topiramate and divalproex in combination with risperidone for acute mania: a randomized open-label study. Prof Neuropsychopharmacol Biol Psychiatry. 2005;29(1):115\u201321.","journal-title":"Prof Neuropsychopharmacol Biol Psychiatry"},{"issue":"5","key":"32_CR84","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s12325-012-0020-1","volume":"29","author":"AC Childress","year":"2012","unstructured":"Childress AC. Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit\/hyperactivity disorder. Adv Ther. 2012;29(5):385\u2013400.","journal-title":"Adv Ther"},{"issue":"5","key":"32_CR85","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1089\/cap.2009.0051","volume":"19","author":"JB Penzner","year":"2009","unstructured":"Penzner JB, Dudas M, Saito E, et al. Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality. J Child Adolesc Psychopharmacol. 2009;19(5):563\u201373.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"32_CR86","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1089\/104454604773840508","volume":"41","author":"WB Daviss","year":"2004","unstructured":"Daviss WB, Scott J. A chart review of cyproheptadine for stimulant-induced weight loss. J Child Adolesc Psychopharmacol. 2004;41(1):65\u201373.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"4","key":"32_CR87","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1089\/cap.2010.0152","volume":"21","author":"D Safer","year":"2004","unstructured":"Safer D. Age-grouped differences in adverse drug events from psychotropic medication. J Child Adolesc Psychopharmacol. 2004;21(4):299\u2013309.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"32_CR88","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1177\/0004867412446494","volume":"46","author":"J Jureidini","year":"2012","unstructured":"Jureidini J. Key opinion leaders in psychiatry: a conflicted pathway to career advancement. Aust N Z J Psychiatry. 2012;46:495\u20137.","journal-title":"Aust N Z J Psychiatry"},{"key":"32_CR89","unstructured":"Cutting edge information. Key opinion leaders (PH122) relationship management and segmentation data. 2009 Extracts. http:\/\/www.cuttingedgeinfo.com\/research\/medical-affairs\/key-opinion-leaders\/ . Accessed Feb 2012 (Full copy available from Jon Jureidini)."},{"key":"32_CR90","unstructured":"Allen S. Backlash on bipolar diagnoses in children: MGH psychiatrist\u2019s work stirs debate. Boston Globe June 17, 2007. http:\/\/www.boston.com\/yourlife\/health\/diseases\/articles\/2007\/06\/17\/backlash_on_bipolar_diagnoses_in_children\/ ."},{"issue":"10","key":"32_CR91","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1056\/NEJMp0911494","volume":"362","author":"E Basch","year":"2010","unstructured":"Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med. 2010;362(10):865\u20139.","journal-title":"N Engl J Med"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-013-0032-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40272-013-0032-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-013-0032-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T06:19:13Z","timestamp":1715494753000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40272-013-0032-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,12]]},"references-count":91,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["32"],"URL":"https:\/\/doi.org\/10.1007\/s40272-013-0032-6","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,12]]}}}